Redox responsive release typically involves the use of nanoparticles, polymers, or other carriers that are sensitive to changes in the redox environment. These carriers can be designed to degrade or change their structure in response to elevated ROS or GSH levels, thereby releasing the encapsulated drugs specifically within the cancer cells.
